Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGCNASDAQ:FULCNASDAQ:MOLNNYSE:ZVIA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.19-4.0%$1.42$0.77▼$8.65$227.99M0.756.13 million shs9.74 million shsFULCFulcrum Therapeutics$7.17+2.6%$5.70$2.32▼$10.13$377.58M2.4955,359 shs1.03 million shsMOLNMolecular Partners$3.58-8.0%$3.89$3.36▼$12.22$157.06M1.1215,367 shs3,191 shsZVIAZevia PBC$3.26+5.2%$2.64$0.62▼$4.99$230.09M0.85505,968 shs1.49 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-4.03%-17.93%-34.97%+8.18%-82.63%FULCFulcrum Therapeutics+2.58%+5.44%+11.34%+130.55%+7.34%MOLNMolecular Partners-2.74%-6.92%-11.69%-8.44%-62.71%ZVIAZevia PBC+4.32%+8.49%+16.43%+51.63%+349.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth2.4389 of 5 stars2.52.00.00.02.60.01.3FULCFulcrum Therapeutics0.145 of 5 stars1.30.00.00.00.02.50.0MOLNMolecular Partners2.3222 of 5 stars3.85.00.00.00.00.00.6ZVIAZevia PBC0.9693 of 5 stars1.05.00.00.01.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.00Sell$2.0068.07% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$6.29-12.33% DownsideMOLNMolecular Partners 3.50Strong Buy$12.00235.20% UpsideZVIAZevia PBC 2.00Hold$3.383.53% UpsideCurrent Analyst Ratings BreakdownLatest ZVIA, CGC, FULC, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CGCCanopy GrowthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight5/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/15/2025FULCFulcrum TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$10.005/5/2025ZVIAZevia PBCTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$3.00 ➝ $3.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$225.65M0.97N/AN/A$1.90 per share0.63FULCFulcrum Therapeutics$80M4.84N/AN/A$4.51 per share1.59MOLNMolecular Partners$5.65M25.59N/AN/A$3.99 per share0.90ZVIAZevia PBC$155.05M1.56N/AN/A$0.59 per share5.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$4.04N/AN/AN/A-195.76%-88.54%-40.78%8/8/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$0.07N/AN/AN/AN/A-0.20%-0.19%7/30/2025 (Estimated)MOLNMolecular Partners-$61.39M-$1.92N/AN/AN/A-1,043.01%-42.20%-38.12%8/25/2025 (Estimated)ZVIAZevia PBC-$20M-$0.31N/AN/AN/A-12.58%-35.52%-23.13%8/6/2025 (Estimated)Latest ZVIA, CGC, FULC, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/7/2025Q1 2025ZVIAZevia PBC-$0.10-$0.06+$0.04-$0.08$37.15 million$38.02 million5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AZVIAZevia PBCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.623.122.10FULCFulcrum TherapeuticsN/A28.7128.71MOLNMolecular PartnersN/A15.2815.28ZVIAZevia PBCN/A2.341.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%FULCFulcrum Therapeutics89.83%MOLNMolecular Partners26.55%ZVIAZevia PBC53.21%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth1.30%FULCFulcrum Therapeutics7.00%MOLNMolecular Partners5.93%ZVIAZevia PBC12.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150183.87 million181.48 millionOptionableFULCFulcrum Therapeutics10053.98 million50.20 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableZVIAZevia PBC13074.22 million64.91 millionOptionableZVIA, CGC, FULC, and MOLN HeadlinesRecent News About These CompaniesZevia: Higher Valuation Provides A Weak Risk-To-Reward (Rating Downgrade)June 19, 2025 | seekingalpha.com5 Soft Drink Stocks to Watch as Health Trends Shake Up the IndustryJune 9, 2025 | zacks.comShort Interest in Zevia PBC (NYSE:ZVIA) Decreases By 13.2%June 5, 2025 | marketbeat.comJane Street Group LLC Has $531,000 Stake in Zevia PBC (NYSE:ZVIA)May 30, 2025 | marketbeat.comConsumer Sentiment Hits New Low: 3 Consumer Staple Stocks to BuyMay 23, 2025 | zacks.comAnalysts Conflicted on These Consumer Goods Names: Coca Cola Femsa SAB De CV (KOF), Sprouts Farmers (SFM) and Zevia PBC (ZVIA)May 16, 2025 | theglobeandmail.comZevia PBC (NYSE:ZVIA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comCautious Optimism for Zevia PBC Amid Promising Developments and Market ChallengesMay 12, 2025 | tipranks.comZevia PBC (ZVIA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comEarnings call transcript: Zevia’s Q1 2025 sees improved margins, reduced lossesMay 9, 2025 | investing.comQ1 2025 Zevia PBC Earnings CallMay 8, 2025 | uk.finance.yahoo.comZevia PBC (ZVIA) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic Expansion ...May 8, 2025 | finance.yahoo.comCautious Outlook on Zevia PBC: Hold Rating Amid Growth UncertaintiesMay 8, 2025 | tipranks.comZevia (ZVIA) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comZevia Announces First Quarter 2025 ResultsMay 7, 2025 | businesswire.comZevia Announces May Conference ParticipationApril 30, 2025 | finance.yahoo.comZevia to Announce First Quarter 2025 Earnings Results on May 7, 2025April 23, 2025 | businesswire.comCoca-Cola Is the King of the Mountain, But These 8 Beverage Companies Are Gaining SteamApril 20, 2025 | 247wallst.comZevia: Distribution Gains Are Needed For ProfitabilityMarch 18, 2025 | seekingalpha.comZevia PBC (ZVIA): the Best Vegan Stock to Buy According to AnalystsMarch 7, 2025 | insidermonkey.comZevia price target raised to $2.75 from 95c at Morgan StanleyMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZVIA, CGC, FULC, and MOLN Company DescriptionsCanopy Growth NASDAQ:CGC$1.19 -0.05 (-4.03%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.24 +0.05 (+3.78%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Fulcrum Therapeutics NASDAQ:FULC$7.17 +0.18 (+2.58%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$7.04 -0.13 (-1.80%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Molecular Partners NASDAQ:MOLN$3.60 -0.29 (-7.33%) As of 06/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Zevia PBC NYSE:ZVIA$3.26 +0.16 (+5.16%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$3.31 +0.05 (+1.53%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevia PBC, a beverage company, develops, markets, sells, and distributes various carbonated beverages in the United States and Canada. It offers soda, energy drinks, organic tea, and kidz drinks. The company offers its products through a network of food, drug, warehouse club, mass, natural, convenience, and e-commerce channels, as well as grocery distributors and natural product stores and specialty outlets. It provides its products under the Zevia brand name. The company was founded in 2007 and is headquartered in Encino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
